SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bellicum Pharmaceuticals, Inc.

NEW YORK, Jan. 31, 2018 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ: BLCM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

The investigation concerns whether Bellicum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On January 30, 2018, post-market, Bellicum issued a press release announcing “that the Company has received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501”, Bellicum’s lead product candidate, “have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.” On this news, Bellicum’s share price has fallen sharply during intraday trading on January 31, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]